Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
McKinsey
AstraZeneca
Mallinckrodt
McKesson

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Patent: 8,246,960

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,246,960
Title:Methods and compositions for generating bioactive assemblies of increased complexity and uses
Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.
Inventor(s): Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Woodland Park, NJ)
Assignee: IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:13/021,302
Patent Claims:see list of patent claims

Details for Patent 8,246,960

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 1998-06-19 ⤷  Try it Free 2025-10-19
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab Injection 103770 2004-07-23 ⤷  Try it Free 2025-10-19
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Try it Free 2025-10-19
Genentech, Inc. XOLAIR omalizumab For Injection 103976 2003-06-20 ⤷  Try it Free 2025-10-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
McKinsey
Express Scripts
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.